Investor Presentation: First Nine Months of 2020
72
Investor presentation First nine months of 2020
Acquisition of Corvidia Therapeutics supports Novo Nordisk's
ambition within cardiovascular disease
Data from a phase 2a trial using ziltivekimab
in CKD stage 5 patients with inflammation
Trial design of the phase 2b (RESCUE)
7.5 mg Q4W (66 patients)
Placebo
Ziltivekimab
N=61
12
2 mg
16
6 mg
16
20 mg
CKD stage
15 mg Q4W (66 patients)
17
3-5 hsCRP
>2 mg/L
30 mg Q4W (66 patients)
% of patients
hsCRP<2.0
mg/L, Week 12
Placebo Q4W (66 patients)
14.3
43.8
60.0
90.9*
24-week treatment
Conclusions:
.
Ziltivekimab effectively reduces C-reactive protein (CRP) in
patients with CKD on dialysis
Ziltivekimab substantially reduced markers of
inflammation with a trend towards improving NT-proBNP
without adversely affecting lipoprotein lipids, neutrophils
or platelets
Primary endpoint
.
Reduction of inflammation measured as reduction in
C-reactive protein
Purpose/timing
•
Determine a dose for a potential phase 3 CVOT
Source: https://www.ahajournals.org/doi/10.1161/circ.140.suppl_1.13727.
hsCRP: High sensitivity C-reactive protein; CKD: chronic kidney disease; NT-proBNP: N-terminal-pro hormone BNP; Q4W: intravenously every 4 weeks; CVOT: cardiovascular outcomes trial
Novo NordiskⓇView entire presentation